Programmable genomic DNA loci with associated histone tails

Programmable genomic DNA loci with associated histone tails refer to specific regions of the genome targeted for epigenetic modulation to control gene expression. This therapeutic approach utilizes engineered DNA-binding proteins, such as zinc fingers or catalytically inactive Cas9 (dCas9), to recruit chromatin-modifying enzymes to precise locations (Nuñez et al., 2021). These enzymes alter the post-translational modifications on histone tails, such as H3K27 acetylation or H3K9 methylation, which in turn dictates whether the associated DNA is transcriptionally active or silent (Hilton et al., 2015). This target class is highly relevant in oncology, where it can be used to silence overexpressed oncogenes like MYC or reactivate silenced tumor suppressors (Omega Therapeutics, 2023). Unlike traditional CRISPR-Cas9 gene editing, targeting histone tails does not involve double-strand breaks, potentially reducing the risk of genomic instability. However, therapeutic challenges include ensuring the specificity of the epigenetic marks and managing the immunogenicity of the delivery systems and effector proteins (Tune Therapeutics, 2024). The ability to "tune" gene expression rather than permanently deleting it offers a more nuanced approach to treating complex diseases. Clinical-stage candidates like OTX-2002 are currently exploring this mechanism to treat hepatocellular carcinoma by targeting the MYC promoter. As the field advances, these programmable loci represent a versatile platform for addressing a wide range of genetic and acquired conditions.

Other names

Epigenome editing targetTargeted chromatin modification siteProgrammable epigenetic locusdCas9-effector targetTargeted histone modification site

Targeted recruitment of epigenetic effectors (e.g., methyltransferases, acetyltransferases) to specific genomic coordinates to modulate chromatin structure and gene transcription.